Product Information
RIVASTIGMINE 4.5 MG CAPSULE is a generic product labeled by Chartwell RX LLC, priced at $0.1744 per EA under NDC 62135090260. Its NADAC has been published 173 times since Jun 14, 2023.
FDA first approved this application on Sep 28, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
4.5 mg/1
Manufacturer
Chartwell RX LLCNDC
62135090260
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
RIVASTIGMINE TARTRATEApproval Type
Generic (ANDA)
FDA Application
ANDA207797FDA Approved
9/28/2017
TE Code
AB
On Market Since
9/28/2017
Pharmacological Classes
Price Statistics
The NADAC for RIVASTIGMINE 4.5 MG CAPSULE has been published 173 times since Jun 14, 2023, and over the history we have for it it has declined 14.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1744 per EA |
|---|---|
| All-time high | $0.2702 (Feb 14, 2024) |
| All-time low | $0.1744 (Sep 23, 2026) |
| 52-week high | $0.2100 |
| 52-week low | $0.1744 |
| Median price | $0.2042 |
| Average price | $0.2092 |
| Largest weekly change | -23.0% (Feb 21, 2024) |
| Weeks tracked | 173 |
| Tracking since | Jun 14, 2023 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Chartwell RX LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Rivastigmine Tartrate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cholinesterase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RIVASTIGMINE 4.5 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for RIVASTIGMINE 4.5 MG CAPSULE, manufactured by Chartwell RX LLC, is $0.1744 per EA (NDC 62135090260), effective Sep 30, 2026.
How has the price of RIVASTIGMINE 4.5 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for RIVASTIGMINE 4.5 MG CAPSULE has declined 14.0%. It has been tracked across 173 weekly CMS publications since Jun 14, 2023.
What are the highest and lowest recorded NADAC prices for RIVASTIGMINE 4.5 MG CAPSULE?
Since Jun 14, 2023, the NADAC for RIVASTIGMINE 4.5 MG CAPSULE has ranged from a low of $0.1744 (Sep 23, 2026) to a high of $0.2702 (Feb 14, 2024), with a median of $0.2042 per EA.
Are there cheaper alternatives to RIVASTIGMINE 4.5 MG CAPSULE?
5 manufacturers publish a NADAC-priced product with the same active ingredient and strength as RIVASTIGMINE 4.5 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures RIVASTIGMINE 4.5 MG CAPSULE?
RIVASTIGMINE 4.5 MG CAPSULE (NDC 62135090260) is labeled by Chartwell RX LLC, and CMS classifies it as a generic product.